Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 10;22(1):261.
doi: 10.1186/s12886-022-02458-z.

Evaluation of a self-imaging SD-OCT system designed for remote home monitoring

Judy E Kim  1 , Oren Tomkins-Netzer  2 , Michael J Elman  3 , David R Lally  4 , Michaella Goldstein  5 , Dafna Goldenberg  6 , Shiri Shulman  6 , Gidi Benyamini  7 , Anat Loewenstein  5
Affiliations

Evaluation of a self-imaging SD-OCT system designed for remote home monitoring

Judy E Kim et al. BMC Ophthalmol. .

Abstract

Purpose: To compare identification rates of retinal fluid of the Notal Vision Home Optical Coherence Tomography (OCT) device (NVHO) when used by people with age-related macular degeneration (AMD) to those captured by a commercial OCT.

Methods: Prospective, cross-sectional study where patients underwent commercial OCT imaging followed by self-imaging with either the NVHO 2.5 or the NVHO 3 in clinic setting. Outcomes included patients' ability to acquire analyzable OCT images with the NVHO and to compare those with commercial images.

Results: Successful images were acquired with the NVHO 2.5 in 469/531 eyes (88%) in 264/290 subjects (91%) with the mean (SD) age of 78.8 (8.8); 153 (58%) were female with median visual acuity (VA) of 20/40. In the NVHO 3 cohort, 69 eyes of 45 subjects (93%) completed the self-imaging. Higher rates of successful imaging were found in eyes with VA ≥ 20/320. Positive percent agreement/negative percent agreement for detecting the presence of subretinal and/or intraretinal fluid when reviewing for fluid in three repeated volume scans were 97%/95%, respectively for the NVHO v3.

Conclusion: Self-testing with the NVHO can produce high quality images suitable for fluid identification by human graders, suggesting the device may be able to complement standard-of-care clinical assessments and treatments.

Keywords: Age-related macular degeneration; HOME OCT; Home monitoring.

PubMed Disclaimer

Conflict of interest statement

All authors are consultants to Notal Vision.

Figures

Fig. 1
Fig. 1
Forehead positioning feedback. Left image: Patient view with forehead not on forehead rest. Right image: Patient view with forehead gently touching the forehead rest
Fig. 2
Fig. 2
Visual X-Y direction head positioning and eye fixation feedback. Left image: Patient view requiring moving head laterally. Right image: Patient view when lateral alignment achieved
Fig. 3
Fig. 3
Flow diagrams illustrating the participants enrollment and exclusion throughout the studies
Fig. 4
Fig. 4
Rates of successful self-imaging with the NVHO 2.5 device by visual acuity
Fig. 5
Fig. 5
Positive Precent Agreement (PPA), Negative Precent Agreement (NPA) and Overall Rates of Agreement (ORA) of NVHO 2.5 device versus commercial OCT by visual acuity
Fig. 6
Fig. 6
Comparison of the fluid volume identified on Cirrus vs the NVHO V2.5
Fig. 7
Fig. 7
Rates of successful imaging with the NVHO 3 device by visual acuity
Fig. 8
Fig. 8
Positive Precent Agreement (PPA), Negative Precent Agreement (NPA) and Overall Rates of Agreement (ORA) of NVHO 3 device versus commercial OCT by visual acuity
Fig. 9
Fig. 9
a Left: Spectralis OCT image; Right: NVHO 3 image. b Left: Spectralis OCT image; Right: NVHO 3 image. c An example of comparison of a series of scans over 42 days – NVHO 3 images. d An example of comparison of a series of scans over 42 days – Spectralis images
See this image and copyright information in PMC

References

    1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728–1738. doi: 10.1016/S0140-6736(12)60282-7. - DOI - PubMed
    1. Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640–1642. doi: 10.1001/archopht.1984.01040031330019. - DOI - PubMed
    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group ftMS Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi: 10.1056/NEJMoa054481. - DOI - PubMed
    1. Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, Morlet N, Young S, Barthelmes D, Gillies MC, et al. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology. 2016;123(11):2393–2400. doi: 10.1016/j.ophtha.2016.07.012. - DOI - PubMed
    1. Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, Clark WL, Abdelfattah NS, Sadda SR, TREX-AMD Study Group Randomized Trail of treat-and-extend versus monthly dosing for Neovascular age related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina. 2017;1(4):314–321. doi: 10.1016/j.oret.2016.12.004. - DOI - PubMed